RecruitingNCT07109154

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study (Prospective and Survey); Evaluation Patterns of Choice in First Line Treatment of Metastatic NSCLC


Sponsor

AstraZeneca

Enrollment

200 participants

Start Date

Nov 25, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.


Eligibility

Plain Language Summary

Simplified for easier understanding

This is an observational registry study — no experimental treatment involved — collecting detailed information on patients in Spain with advanced non-small cell lung cancer (NSCLC) who are starting their first-line treatment. The goal is to understand how treatment patterns in real clinical practice compare to established medical guidelines. **You may be eligible if:** - You have been diagnosed with advanced (unresectable or metastatic) non-small cell lung cancer - You are starting your first-line oncological treatment at one of the participating centers between 2025 and 2026 - You are over 18 years old - Your medical records are available electronically **You may NOT be eligible if:** - Your lung cancer is at an early stage that can be treated locally (surgery or radiation) - Your cancer is small cell lung cancer, neuroendocrine tumor, or has non-epithelial features - You have already been enrolled in the PACIFIC follow-up protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(7)

Research Site

Recife, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Salvador, Brazil

Research Site

Salvador, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07109154


Related Trials